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Abstract 22 
Four CreER lines that are commonly used in the auditory field to label cochlear 23 
supporting cells (SCs) are expressed in multiple SC subtypes, with some lines also 24 
showing reporter expression in hair cells (HCs). We hypothesized that altering the 25 
tamoxifen dose would modify CreER expression and target subsets of SCs. We also 26 
used two different reporter lines, ROSA26tdTomato and CAG-eGFP, to achieve the same 27 
goal. Our results confirm previous reports that Sox2CreERT2 and Fgfr3-iCreERT2 are not 28 
only expressed in neonatal SCs, but also in HCs. Decreasing the tamoxifen dose did 29 
not reduce HC expression for Sox2CreERT2, but changing to the CAG-eGFP reporter 30 
decreased reporter-positive HCs 7-fold. However, there was also a significant decrease 31 
in the number of reporter-positive SCs. In contrast, there was a large reduction in 32 
reporter-positive HCs in Fgfr3-iCreERT2 mice with the lowest tamoxifen dose tested, yet 33 
only limited reduction in SC labeling. The targeting of reporter expression to inner 34 
phalangeal and border cells was increased when Plp-CreERT2 was paired with the CAG-35 
eGFP reporter, however the total number of labeled cells decreased. Changes to the 36 
tamoxifen dose or reporter line with Prox1CreERT2 caused minimal changes. Our data 37 
demonstrate that modifications to the tamoxifen dose or the use of different reporter 38 
lines may be successful in narrowing the numbers and/or types of cells labeled, but 39 
each CreER line responded differently. When the ROSA26tdTomato reporter was 40 
combined with any of the four CreER lines, there was no difference in the number of 41 
tdTomato-positive cells after one or two injections of tamoxifen given at birth. Thus 42 
tamoxifen-mediated toxicity could be reduced by only giving one injection. While the 43 
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CAG-eGFP reporter consistently labeled fewer cells, both reporter lines are valuable 44 
depending on the goal of the study.  45 
 46 
Keywords: Plp-CreER, Sox2-CreER, Fgfr3-iCreER, Prox1-CreER, mouse genetics, 47 
Cre/loxP 48 
 49 
Introduction 50 
The mammalian cochlea is a highly organized structure containing sensory hair cells 51 
(HCs) surrounded by supporting cells (SCs), which are divided into subtypes based on 52 
location (Figure 1A). Cells of the greater epithelial ridge (GER), inner phalangeal cells 53 
(IPhCs), and border cells (BCs) are located medial to inner HCs (IHCs). Inner pillar cells 54 
(IPCs) and outer pillar cells (OPCs) separate IHCs and outer HCs (OHCs). Deiters’ cells 55 
(DCs) surround OHCs with Hensen cells (HeCs) and Claudius cells (CCs) located 56 
lateral to the last row of OHCs (Raphael and Altschuler, 2003). While HCs and SCs are 57 
distinct cell types, they are derived from the same pool of progenitor cells (Yang et al., 58 
2010; Cai et al., 2013; Driver et al., 2013). 59 
 60 
Much research has focused on HCs including studies of planar cell polarity (Denman-61 
Johnson and Forge, 1999; Lewis and Davies, 2002), mechanotransduction (Hudspeth 62 
and Corey, 1977; LeMasurier and Gillespie, 2005), otoprotection (Huang et al., 2000; 63 
Lefebvre et al., 2002), and regeneration (Corwin and Warchol, 1991; Rubel et al., 1995). 64 
While less is known about SCs, several functions have been described including 65 
protection of HCs from excitotoxicity (Spicer and Schulte, 1996; Kikuchi et al., 2000; 66 
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Boettger et al., 2002; Furness et al., 2002), phagocytosis of dying HCs (Abrashkin et al., 67 
2006; Taylor et al., 2008; Anttonen et al., 2014), and sealing the epithelial surface after 68 
HC death (McDowell et al., 1989; Raphael and Altschuler, 1991a, b). Studies have also 69 
shown that SCs release factors which promote the formation of synapses and survival 70 
of HCs and auditory nerves (Pirvola et al., 1992; Flores-Otero et al., 2007; Sugawara et 71 
al., 2007; Tritsch et al., 2007; Gomez-Casati et al., 2010; Tritsch and Bergles, 2010; 72 
Zuccotti et al., 2012). In the neonatal mouse cochlea, SCs are the source of 73 
regenerated HCs (Bramhall et al., 2014; Cox et al., 2014). These functions have been 74 
attributed to SCs as a group, with little known about the function of individual SC 75 
subtypes, primarily because tools are limited.  76 
 77 
Genetically-modified mouse models that target cochlear cells have provided critical 78 
tools to increase our understanding of inner ear physiology and response to damage. 79 
The CreER/loxP system, which allows cell type-specific and temporal control of gene 80 
expression, has been used to delete or over-express genes, to label cell populations for 81 
fate-mapping, and to ablate specific cell types. Here, we used four CreER alleles known 82 
to target broad populations of SCs. The CreER enzyme driven by both the Fgfr3-83 
iCreERT2 and Sox2CreERT2 lines is also expressed in neonatal HCs (Cox et al., 2012; 84 
Bramhall et al., 2014; Walters et al., 2015). We hypothesized that modifying the 85 
tamoxifen induction paradigm and/or changing the paired reporter line would label 86 
subpopulations of SCs as well as decrease HC labeling in Fgfr3-iCreERT2 and 87 
Sox2CreERT2 lines. This hypothesis is based, in part, on previous studies showing that the 88 
ROSA26tdTomato reporter produces a brighter fluorescent protein that is more stable than 89 
the fluorophores produced by other reporter lines such as CAG-eGFP or Rosa26LacZ 90 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
5 
 
(Madisen et al., 2010). With the Fgfr3-iCreERT2 line, a 10-fold reduction in tamoxifen or 91 
changing to the CAG-eGFP reporter produced a large reduction of labeled OHCs. 92 
However, the number of reporter-positive SCs also decreased. Reducing the tamoxifen 93 
dose in Sox2CreERT2+/-::ROSA26tdTomato/+ mice produced a minimal effect. However, 94 
changing to the CAG-eGFP reporter reduced reporter-positive HCs and SCs. Plp-95 
CreERT2 is largely expressed in IPhCs/BCs of the neonatal cochlea with some PCs/DCs 96 
also labeled. Reduction in tamoxifen dose had a minimal effect when the 97 
ROSA26tdTomato reporter was used. However, using the CAG-eGFP reporter with a 98 
reduced tamoxifen dose, fewer PCs/DCs were labeled, but this also decreased the 99 
number of reporter-positive IPhCs/BCs. As previously described, Prox1CreERT2 is limited 100 
to PCs/DCs in the neonatal cochlea, with relatively fewer IPCs labeled. Alterations in 101 
tamoxifen dose caused few changes in labeled cells.  102 
 103 
Materials and Methods 104 
Mice 105 
Sox2CreERT2 (stock #17593; Arnold et al., 2011), Plp-CreERT2 (stock # 5975; Doerflinger 106 
et al., 2003), and ROSA26CAG-loxP-stop-loxP-tdTomato (ROSA26tdTomato) mice, also referred to 107 
as Ai14, (stock #7914; Madisen et al., 2010) were obtained from The Jackson 108 
Laboratory (Bar Harbor, ME).  Fgfr3-iCreERT2 mice (Rivers et al., 2008; Young et al., 109 
2010) were provided by Dr. William Richardson (University College London, UK), 110 
Prox1CreERT2 mice (Srinivasan et al., 2007) were provided by Dr. Guillermo Oliver (St. 111 
Jude Children’s Research Hospital, Memphis, TN) and CAG-loxP-stop-loxP-eGFP 112 
(CAG-eGFP) mice (Nakamura et al., 2006) were provided by Dr. Jeffery Robbins 113 
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(Cincinnati Children’s Hospital, Cincinnati, OH).  Genotyping for all mouse lines was 114 
performed by Transnetyx, Inc. (Cordova, TN).  Mice of both genders were used and all 115 
animal work was performed in accordance with approved animal protocols from the 116 
Institutional Animal Care and Use Committee at Southern Illinois University School of 117 
Medicine. 118 
 119 
Tamoxifen Injections 120 
CreER recombination was induced by intraperitoneal (IP) injections of tamoxifen 121 
(Sigma-Aldrich – St. Louis, MO) dissolved in 100% corn oil. Mice received one injection 122 
per day on either postnatal day (P) 0, P1, or on both P0 and P1 with the dose per 123 
injection ranging from 0.3 mg/40 g to 5 mg/40 g.  Stock solutions were diluted so that 124 
the total volume of each injection remained the same. To measure CreER leakiness, 125 
samples that were CreER-positive and reporter-positive but did not receive tamoxifen 126 
were analyzed as controls. Samples were evaluated between P5-P7.   127 
 128 
Immunostaining 129 
Samples were post-fixed in 4% paraformaldehyde overnight (Polysciences, Inc – 130 
Warrington, PA) and subsequently stored in 10 mM Phosphate Buffered Saline (Sigma-131 
Aldrich – St. Louis, MO) at 4° C.  Cochleae were dissected into apical, middle, and 132 
basal sections using a whole-mount or surface preparation method. Routine 133 
immunostaining was performed on free-floating cochlear turns as previously described 134 
(Montgomery and Cox, 2016) with the following primary antibodies: anti-myosin VIIa 135 
(1:200, cat #25-6790, Proteus BioSciences – Ramona, CA), anti-Sox2 (1:500, cat #sc-136 
17320, Santa Cruz – Dallas, TX), anti-GFP (1:1000, cat #ab13970, Abcam – 137 
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Cambridge, MA), and anti-GFP conjugated to Alexa 488 (1:50 cat#A21311, Invitrogen – 138 
Grand Island, NY). All secondary antibodies were Alexa-conjugated from Invitrogen 139 
(Waltham, MA) and were used at a 1:1000 dilution.  Images were taken using a Leica 140 
SP5 confocal microscope and image analysis was performed using Leica LAS AF LITE 141 
software.  142 
 143 
Cell counts  144 
HCs and SCs were identified by immunostaining for myosin VIIa and Sox2, respectively. 145 
Myosin VIIa is expressed in the cytoplasm of HCs and Sox2 is expressed in SC nuclei, 146 
while both tdTomato and eGFP are expressed throughout the cell in both cytoplasm and 147 
nuclei. SC subtypes that expressed either the tdTomato or eGFP reporter were 148 
quantified in two randomly chosen 200 µm regions per cochlear turn, averaged, and 149 
expressed as a percentage of labeled cells compared to total cells. For the Fgfr3-150 
iCreERT2 and Sox2CreERT2 lines, all labeled SC subtypes were pooled into one value. For 151 
the Plp-CreERT2 and Prox1CreERT2 lines, SC subtypes were counted individually for 152 
IPCs, OPCs, DCs, and IPhC/BCs.  153 
 154 
Reporter labeling in HCs was detected in Fgfr3-iCreERT2 and Sox2CreERT2 lines. For the 155 
ROSA26tdTomato reporter, the entire organ of Corti was imaged, measured, and divided 156 
into six equal sections for quantification of tdTomato-positive HCs to determine if a 157 
gradient of tdTomato expression was present. For the CAG-eGFP reporter, eGFP-158 
positive HCs were quantified in 2 sections: a 250 µm region at the most apical tip 159 
(where the majority of eGFP-positive cells were found) and the rest of the organ of 160 
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Corti. Data for both reporter lines are expressed as a percentage of the reporter-positive 161 
HCs compared to the total HCs within each region.  162 
 163 
Statistical analysis 164 
All data are presented as mean ± SEM.  One-way or two-way ANOVA followed by 165 
Tukey’s post-hoc tests, Student’s t-test, and Pearson’s correlations were performed 166 
using Graphpad Prism 6.0 2 (Graphpad Software Inc – La Jolla, CA). 167 
 168 
 169 
Results 170 
The CreER/loxP system allows cell-type specific gene expression through the use of 171 
cell-type specific promoters that drive expression of the Cre enzyme. Temporal control 172 
is achieved by fusing a modified estrogen receptor (ER) to Cre, which restricts the 173 
CreER protein to the cytoplasm. Only in the presence of tamoxifen will CreER 174 
translocate to the nucleus for excision of loxP sites (Feil et al., 1996; Hayashi and 175 
McMahon, 2002). Using four independent CreER mouse lines (Fgfr3-iCreERT2, 176 
Sox2CreERT2, Plp-CreERT2, and Prox1CreERT2) that have previously been shown to label 177 
broad populations of SCs in the neonatal cochlea, we sought to label subpopulations of 178 
SCs by altering the tamoxifen induction paradigm and/or reporter line.  179 
 180 
The ROSA26tdTomato reporter line was developed to improve the fluorescent labeling of 181 
cells in a Cre-dependent manner over standard reporter lines such as CAG-eGFP. It 182 
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uses two ubiquitously expressed promoters (ROSA26 and CAG) to drive expression of 183 
tdTomato, as well as the woodchuck hepatitis virus post-transcriptional regulatory 184 
element (WPRE) to enhance mRNA stability. Endogenous fluorescence of tdTomato is 185 
~2.8 times brighter than eGFP and is readily detected, whereas as detection of eGFP 186 
often requires amplification with immunostaining prior to imaging (Madisen et al., 2010; 187 
Madisen et al., 2015).  Therefore different patterns of reporter labeling are seen when 188 
ROSA26tdTomato and CAG-eGFP reporter lines are used with the same CreER allele and 189 
tamoxifen induction paradigm. We also tested for Cre leakage, which can occur when 190 
some of the CreER enzyme enters the nucleus in the absence of tamoxifen. To 191 
determine the leakiness of these four CreER lines, we performed control experiments 192 
using CreER-positive::reporter-positive mice that did not receive tamoxifen.   193 
 194 
Fgfr3-iCreERT2  195 
Fibroblast growth factor receptor 3 (Fgfr3) is necessary for development of PCs in the 196 
organ of Corti (Colvin et al., 1996). At P0, Fgfr3 expression is thought to be confined to 197 
PCs and DCs in the lateral compartment of the cochlea (Peters et al., 1993; Mueller et 198 
al., 2002; Pirvola et al., 2002; Hayashi et al., 2007). However recent single-cell RNA-199 
seq analyses have detected a low level of Fgfr3 expression in some HCs at P1-2 (Burns 200 
et al., 2015; Waldhaus et al., 2015). The Fgfr3-iCreERT2 mouse line is a transgenic 201 
allele, where CreER is driven by the Fgfr3 promoter (Young et al., 2010). Previous 202 
characterization of the Fgfr3-iCreERT2 allele showed that after tamoxifen injection at 203 
neonatal ages, reporter expression was detected in the vast majority of PCs and DCs 204 
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within the organ of Corti (Cox et al., 2012). Specifically when Fgfr3-205 
iCreERT2/+::ROSA26tdTomato/+ mice were injected with tamoxifen (3 mg/40 g, IP) at both 206 
P0 and P1, 100% of PCs and DCs expressed tdTomato. However, there were also 25-207 
75% of OHCs labeled (Cox et al., 2012). To verify this expression pattern and to 208 
establish a basis for comparison, we repeated this induction protocol in Fgfr3-209 
iCreERT2/+::ROSA26tdTomato/+ mice and found that 94.4 % ± 5.5% of PCs and DCs were 210 
labeled throughout the organ of Corti (Figure 1B, Table 1). Similar to previously 211 
published results, this dosing paradigm also showed robust labeling of OHCs (43.8% ± 212 
2.9%; Figure 2B, Table 1). To investigate whether there was a gradient of HC labeling 213 
across cochlear turns, the organ of Corti was divided into six sections of equal length 214 
(Figure 2A) and the percentage of labeled OHCs was counted within each section. The 215 
percentage of tdTomato+ OHCs declined in an apical to basal gradient (98.5% ± 0.7% 216 
in the first segment of apex and 13.2% ± 3.1% in the last segment of the base; Pearson 217 
correlation coefficient r2 = 0.81, P = 0.049; Figure 2B, Table 1). Three tdTomato-positive 218 
IHCs were detected in the apical tip of one sample (data not shown). In addition, no 219 
tdTomato-positive SCs or HCs were detected in controls that were not treated with 220 
tamoxifen (Figure 1B-E, 2B-E).  221 
 222 
To attenuate HC labeling and target only PCs and DCs, Cre-mediated recombination 223 
was induced with a 10-fold lower dose of tamoxifen (0.3 mg/40 g, IP) at P1 only. The 224 
percentage of tdTomato-positive HCs was reduced to 3.9% ± 2.2% of total OHCs 225 
across the entire cochlea (Figure 2B, F-M, Table 1). Yet the apical to basal gradient 226 
remained with 14.6% ± 10.6% OHCs labeled in the first apical section and 0.2% ± 0.2% 227 
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in the most basal section (Pearson correlation coefficient r2 = 0.81, P = 0.049; Figure 228 
2B, F-M, Table 1). However, this dosing paradigm also reduced total PC/DC labeling to 229 
77.7% ± 4.9% (Figure 1B, F-H”’, Table 1). 230 
  231 
Because HC labeling was still present with the reduced tamoxifen dose, Fgfr3-iCreERT2 232 
mice were next paired with the CAG-eGFP reporter. Using the previously published 233 
tamoxifen induction paradigm (3 mg/40 g, IP at P0/P1) in Fgfr3-iCreERT2/+::CAG-234 
eGFP+/loxP mice, we observed 37.8% ± 3.4% eGFP-positive PCs and DCs throughout 235 
the cochlea (Figure 1B, L-N”’, Table 1). However, similar to the 0.3 mg/40 g tamoxifen 236 
paradigm in Fgfr3-iCreERT2/+::ROSA26tdTomato/+ mice, 5.8% ± 2.6% eGFP-positive OHCs 237 
were still detected (Figure 3B, F-M, Table 1). Because the apical tip of the cochlea 238 
contained a large number of eGFP-positive HCs which quickly declined, the cochlea 239 
was divided into two sections for quantification: the first 250 µm of the apex and the 240 
remainder of the cochlea (Figure 3A). Upon quantification, there was a significant 241 
difference between the two regions with the largest amount of OHC labeling in the most 242 
apical section (40.5% ± 6.1% compared to 4.4% ± 2.5%; paired Student’s t test t(2)= 243 
9.822, P =0.0102); Figure 3B, Table 1). No eGFP-positive SCs or HCs were observed in 244 
control animals that were not treated with tamoxifen (Figure 1B, I-K, 3B-E).   245 
 246 
Sox2CreERT2  247 
Sox2 is a transcription factor expressed in all SCs throughout the organ of Corti as well 248 
as in immature HCs (Hume et al., 2007; Dabdoub et al., 2008). Low levels of Sox2 249 
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expression have been detected in some HCs at P1-2 using single-cell RNA-seq 250 
analyses (Burns et al., 2015; Waldhaus et al., 2015). The Sox2CreERT2 mouse line is a 251 
knock-in allele, where CreER was inserted into the endogenous Sox2 locus (Arnold et 252 
al., 2011). Sox2CreERT2 expression has previously been reported in both HCs and SCs in 253 
the neonatal organ of Corti (Bramhall et al., 2014; Walters et al., 2015). When paired 254 
with the ROSA26tdTomato reporter line and tamoxifen (3 mg/40 g, IP) given at P0/P1, 255 
more than 85% of SCs and more than 50% of HCs throughout the cochlea were labeled 256 
(Walters et al., 2015). To determine whether HC labeling could be reduced, we 257 
performed a tamoxifen dose response analysis. For comparison, we repeated the 258 
dosing paradigm from Walters et al., (2015). In Sox2CreERT2+/-::ROSA26tdTomato/+ mice 259 
with tamoxifen (3 mg/40 g, IP) injected at P0/P1, 100% ± 0.0% of SCs from the GER to 260 
HeCs throughout the cochlea expressed tdTomato (Figure 4A, Table 1). 35.3% ± 4.8% 261 
tdTomato-positive HCs were also observed which appeared to decrease in a gradient 262 
from apical to basal turn of the cochlea (Figure 5A, Table 1). To quantify this gradient, 263 
we divided the organ of Corti into six segments of equal length as before (Figure 2A). 264 
No difference was observed between the percentage of IHCs and OHCs labeled in any 265 
of the six segments (Figure 5A). However, the percentage of tdTomato-positive HCs 266 
was 97.2% ± 1.7% in the most apical segment which declined to 2.7%± 1.2% in the 267 
most basal segment (Figure 5A, Table 1; Pearson correlation coefficient r2 = 0.996, P = 268 
0.00002). In addition, Sox2CreERT2+/-::ROSA26tdTomato/+ mice showed some Cre leakiness 269 
with approximately 20 tdTomato-positive SCs detected in the entire cochlea in controls 270 
that did not receive tamoxifen (Figure 4A-D, 5A-D). 271 
 272 
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To determine if a reduced tamoxifen dose leads to a reduced number of labeled HCs, 273 
Sox2CreERT2+/-::ROSA26tdTomato/+ mice were injected with tamoxifen (3 mg/40 g, IP) at P0 274 
only. Again, 99.9% ± 0% of SCs throughout the cochlea were labeled (Figure 4A, E-G”’, 275 
Table 1). There was minimal change in the percentage of tdTomato-labeled HCs 276 
(34.5% ± 4.7%) with no significant reduction seen compared to the dual injection of 277 
tamoxifen (Figure 5A, E-L, Table 1).  278 
 279 
We next used CAG-eGFP+/loxP mice to investigate whether a different reporter would 280 
minimize HC labeling. Sox2CreERT2+/-::CAG-eGFP+/loxP mice were injected with tamoxifen 281 
(3 mg/40 g, IP) at P1 only. Unlike the ROSA26tdTomato reporter, no eGFP-positive cells 282 
were observed in controls that did not receive tamoxifen (Figure 4A, H-J, 6A-D). As 283 
predicted, there was a large reduction in the total number of eGFP-positive HCs with the 284 
majority of the labeled cells located in the apex (Figure 6A, E-L). Therefore, we 285 
quantified eGFP-positive HCs using the same parameters used for FGFR3-286 
iCreERT2/+::CAG-eGFP+/loxP samples (Figure 3A). Throughout the entire organ of Corti, 287 
only 3.2%± 0.4% HCs were labeled with eGFP (Figure 6A, Table 1), which is far less 288 
than the number of tdTomato-positive HCs observed with tamoxifen induction at either 289 
P0 only (34.5%± 4.7%) or P0/P1 (35.3%± 4.8% Figure 5A, Table 1). Within the first 250 290 
μm of the apical tip in Sox2CreERT2+/-::CAG-eGFP+/loxP mice, 44.8% ± 10.8% of HCs were 291 
eGFP-positive, however, only 1.6% ± 0.5%  eGFP-positive HCs were observed 292 
throughout the remainder of the cochlea (paired Student’s t test t(3.967)= 2, P =0.0581, 293 
Figure 6A, Table 1). Parallel to the reduction in eGFP-positive HCs, fewer SCs were 294 
labeled with eGFP throughout the cochlea (66.0% ± 5.9% compared to 100%± 0.0% 295 
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tdTomato-positive SCs with tamoxifen given at P0/P1 and 99.9% ± 0.0% tdTomato-296 
positive SCs with tamoxifen given at P0 only; Figure 4A, K-M”’, Table 1). 297 
  298 
Plp-CreERT2  299 
Proteolipid protein (Plp) is expressed in oligodendrocytes and Schwann cells of the 300 
central and peripheral nervous systems (Fuss et al., 2000; Mallon et al., 2002). In the 301 
mammalian cochlea, Plp is expressed in PCs and DCs in the late embryonic stage 302 
(Morris et al., 2006). Plp-CreERT2 is a transgene that has previously been reported to 303 
label IPhCs and BCs, as well as some PCs and DCs in the neonatal organ of Corti 304 
(Doerflinger et al., 2003; Gomez-Casati et al., 2010; Cox et al., 2012; Mellado Lagarde 305 
et al., 2014). Specifically, Plp-CreERT2/+-::ROSA26eYFP/+ mice injected with tamoxifen (3 306 
mg/40 g, IP) at P0/P1 had 47% eYFP-positive IPhs/BCs, 3.4% eYFP-positive PCs, and 307 
5.2% eYFP-positive DCs with no statistical differences detected among cochlear turns 308 
(Liu et al., 2014). When paired with the ROSA26LacZ reporter and tamoxifen (33 mg/kg, 309 
IP) given from P0-P7, Plp-CreERT2 was expressed only in SCs with the majority of 310 
labeled cells being IPhCs/BCs, but no quantification was given (Gomez-Casati et al., 311 
2010). In Plp-CreERT2/+::Rosa26tdTomato/+ mice given tamoxifen (3 mg/40 g, IP) at P0/P1, 312 
tdTomato expression was observed in 50% of IPhCs/BCs in the apex, 80% of 313 
IPhCs/BCs in the middle and base, and 5-10% of PCs and DCs throughout the whole 314 
cochlea (Cox et al., 2012). Similar to Cox et al. (2012), Mellado Lagarde et al., (2014) 315 
found fewer tdTomato-positive IPhCs/BCs in the apex (25.9%) compared to middle and 316 
basal turns (71.9% and 86.1%, respectively) with the same tamoxifen induction 317 
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paradigm. In order to set a standard with which to compare alternate tamoxifen dosing 318 
paradigms, we repeated the tamoxifen dose published in Cox et al., (2012) and Mellado 319 
Lagarde et al., (2014). Similar to the previous reports, there was an apical to basal 320 
gradient of increasing numbers of tdTomato-positive SCs (Figure 7A, Table 1). 321 
Additionally, fewer IPhCs/BCs expressed tdTomato in the apex (48.2% ± 4.7%) 322 
compared to the middle (79.9% ± 2.5%), and base (89.2% ± 3.7%; one-way ANOVA 323 
F(1.313, 3.940)=71.03, P=0.0010 with Tukey’s multiple comparisons test: Figure 8A, 324 
Table 1). Interestingly, this paradigm also showed SC labeling lateral to IHCs in PCs 325 
and DCs. Specifically, 13.5% ± 4.6% of IPCs and 10.6% ± 2.0% OPCs were labeled 326 
throughout the organ of Corti (Figure 8A-D, Table 1). There also appeared to be a 327 
gradient for DC labeling with fewer tdTomato-positive DCs in the apex (5.8% ± 1.9%) 328 
and middle (9.8% ± 2.8%) than in the base (29.3% ± 4.7%; one-way ANOVA F(1.193, 329 
3.579)=39.29, P=0.0044 with Tukey’s multiple comparisons test; Figure 8D, Table 1).  330 
 331 
We attempted to label only IPhCs/BCs by reducing the tamoxifen dose to one injection 332 
given at either P0 only or P1 only, while maintaining the same concentration (3 mg/40 333 
g). Expression of tdTomato in IPhCs/BCs of Plp-CreERT2/+::Rosa26tdTomato/+ mice that 334 
received tamoxifen at P0 only did not differ from tamoxifen injections given at P1 only or 335 
at both P0/P1 (Figure 7E-J, 8A, Table 1). There was also no difference in the number of 336 
tdTomato-positive IPCs, OPCs, and DCs with a P0 only or P1 only injection compared 337 
to the P0/P1 injection, (Figure 7E-J, 8A-D, Table 1).  338 
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Because reduction in tamoxifen dose did not reduce labeling of PCs/DCs, we next 340 
generated Plp-CreERT2/+-::CAG-eGFP+/loxP mice. When Cre recombination was induced 341 
with tamoxifen (3 mg/40 g, IP) at P0/P1, fewer IPhC/BC were labeled by eGFP than 342 
tdTomato in all turns of the cochlea (apex = 21.8% ± 10.9% eGFP-positive IPhCs/BCs 343 
compared to 48.2% ± 4.7% tdTomato-positive IPhCs/BCs; middle = 28.2% ± 2.1% 344 
eGFP-positive IPhCs/BCs compared to 79.9% ± 2.5% tdTomato-positive IPhCs/BCs; 345 
base = 38.1% ± 3.9% eGFP-positive IPhCs/BCs compared to 89.2% ± 3.7% tdTomato-346 
positive IPhCs/BCs; two-way ANOVA F(2, 45)=30.39, P<0.0001 with Tukey’s multiple 347 
comparisons test; Figure 7Q-S, 8A, Table 1). There was no difference in IPC, OPC, or 348 
DCs labeling between eGFP and tdTomato reporter lines with tamoxifen induction (3 349 
mg/40 g, IP) at P0/P1 (Figure 7Q-S, 8B-D, Table 1). 350 
 351 
Since minimal changes in the Plp-CreERT2 expression pattern occurred with the CAG-352 
eGFP+/loxP reporter, we also investigated a lower dose of tamoxifen to reduce PC/DC 353 
labeling. Reducing the amount of tamoxifen given to Plp-CreERT2/+::CAG-eGFP+/loxP 354 
mice to a single injection (3 mg/40 g, IP) at P0 only reduced the number of eGFP-355 
positive cells only in specific turns of  the cochlea. The eGFP-positive IPhCs/BCs in the 356 
middle turn were reduced (24.3% ± 5.9%) compared to Plp-CreERT2/+::Rosa26tdTomato/+ 357 
mice (79.9% ± 2.5%; two-way ANOVA F(6, 45)=97.06, P<0.0001 with Tukey’s multiple 358 
comparisons test; Figure 7N-P, 8A, Table 1). OPCs were also reduced in the middle 359 
turn (0.0% ± 0.0% eGFP-positive OPCs compared to 15.7% ± 3.4% tdTomato-positive 360 
OPCs; two-way ANOVA F(6, 60)=8.524, P<0.0001 with Tukey’s multiple comparisons 361 
test) and DCs were reduced in the base (5.9% ± 4.8% eGFP-positive DCs compared to 362 
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29.3% ± 4.7% tdTomato-positive DCs; two-way ANOVA F(6, 45)=6.313, P<0.0001 with 363 
Tukey’s multiple comparisons test; Figure 7N-P, 8D, Table 1). Unlike Fgfr3-iCreERT2 364 
and Sox2CreERT2, neither Plp-CreERT2/+::Rosa26tdTomato/+ nor Plp-CreERT2+/-::CAG-365 
eGFP+/loxP mice showed reporter expression in HCs throughout the cochlea. Finally, no 366 
tdTomato-positive or eGFP-positive cells were detected in Plp-CreERT2 control mice 367 
which did not receive tamoxifen (Figure 7A-D, K-M, 8A-D). 368 
 369 
Prox1CreERT2   370 
Prox1 is a transcription factor that is expressed in IPCs, OPCs, and DCs throughout the 371 
neonatal organ of Corti, but is downregulated by ~P14 (Bermingham-McDonogh et al., 372 
2006). The Prox1CreERT2 mouse line is a knock-in allele, where CreER was inserted into 373 
the endogenous Prox1 locus (Srinivasan et al., 2007). Previously, Yu et al. (2010) 374 
characterized Prox1CreERT2 mice using ROSA26LacZ and ROSA26eYFP reporters and 375 
induced Cre recombination with tamoxifen injections (3 mg/40 g, IP) at P0 and P1. LacZ 376 
and eYFP expression were found to only label PCs and DCs, however a small number 377 
of cells were labeled (~13% in the apex, ~10% in the middle, and ~7% in the base, Yu 378 
et al., 2010). When the same tamoxifen induction paradigm was used with the 379 
Rosa26tdTomato reporter, tdTomato also labeled only PCs and DCs, but many more cells 380 
were labeled (Mellado Lagarde et al., 2013). As a basis for comparison, we replicated 381 
this paradigm and quantified tdTomato expression at P6. As previously reported, 382 
Prox1CreERT2 expression was limited to PCs and DCs and no HC labeling was observed. 383 
The tdTomato labeling of PCs and DCs combined was higher in the apex (71.1% ± 384 
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1.2%) and middle (57.2% ± 1.5%) compared to basal turns (44.3% ± 3.3%; one-way 385 
ANOVA F(1.018, 2.036)=37.08, P=0.0248 with Tukey’s multiple comparisons test; 386 
Figure 9A). Similar to the previous report, there was differential labeling among SC 387 
subtypes. Specifically, tdTomato was expressed in fewer IPCs (25.1%± 2.9%) 388 
compared to OPCs (70.1%± 2.6%) and DCs (76.1% ± 0.1%; one-way ANOVA F(1.122, 389 
2.245)=141.1, P=0.0045 with Tukey’s multiple comparisons test; Figure 9N, Table 1). In 390 
addition, the number of tdTomato-positive IPCs was higher in the apex (45.9% ± 1.6%) 391 
compared to the base (7.4% ± 1.2%; one-way ANOVA F(1.021, 2.042)=35.11, 392 
P=0.0260 with Tukey’s multiple comparisons test; Figure 9N, Table 1). There was no 393 
difference in tdTomato-positive OPCs across turns; however, significantly fewer DCs 394 
expressed tdTomato in the base (61.7% ± 4.0%) compared to the apex (89.6% ± 3.0%;) 395 
and middle (80.7% ± 0.6%; one-way ANOVA F(1.302, 2.603)=18.53, P=0.0299 with 396 
Tukey’s multiple comparisons test; Figure 9P, Table 1).  Our results are quite similar to 397 
Mellado-Lagarde et al. (2013). No tdTomato-positive cells were detected in 398 
Prox1CreERT2+/-::Rosa26tdTomato/+ control samples that did not receive tamoxifen (Figure 399 
9A-D, N-P). 400 
 401 
Because so few IPCs were labeled with this induction paradigm, we attempted to 402 
increase the number of tdTomato-positive IPCs by using a higher dose of tamoxifen. In 403 
Prox1CreERT2+/-::Rosa26tdTomato/+ mice injected (IP) with 5 mg/40 g tamoxifen at P0/P1, we 404 
again observed fewer tdTomato-positive IPCs (24.5% ± 0.9%) than OPCs (71.4% ± 405 
1.3%) or DCs (79.5%± 0.4%; one-way ANOVA F(1.038, 2.077)=927.6, P=0.0009 with 406 
Tukey’s multiple comparisons test; Figure 9K-P, Table 1) across the whole cochlea. We 407 
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did not observe an increase in tdTomato labeling in IPCs at this dose (24.5% ± 0.9%) 408 
compared to the 3 mg/40 g dose (25.1%± 2.9%), nor did increasing the dose increase 409 
tdTomato expression in OPCs or DCs (Figure 9K-M, O-P, Table 1). Interestingly, 410 
however, 17 OHCs and 1 IHC in the apical tip of one sample expressed tdTomato with 411 
the 5 mg/40 g dose (Figure 9Q-S).  412 
 413 
We next attempted to eliminate IPC labeling to make Prox1CreERT2 label just OPCs and 414 
DCs using two different adjustments to the tamoxifen regimen. In Prox1CreERT2+/ 415 
::Rosa26tdTomato/+ mice injected with tamoxifen (3 mg/40 g, IP) at P0 only, there were no 416 
differences in the number of tdTomato-positive IPCs, OPCs, or DCs compared to the 417 
P0/P1 injection with the same dose (Figure 9H-J, N-P, Table 1). Similarly, when the 418 
tamoxifen dose was reduced to 0.75 mg/40 g (IP) at P0 only, there was no significant 419 
difference in the number of tdTomato-positive IPCs (16.8% ± 4.0%) compared to the 3 420 
mg/40 g dose given at P0/P1 (25.1% ± 2.9%), however this number was significantly 421 
lower compared to the 3 mg/40 g dose given at P0 only (33.4% ± 2.4%; one-way 422 
ANOVA F(4, 10)=25.88, P<0.0001 with Tukey’s multiple comparisons test, Figure 9E-G, 423 
N, Table 1).  Additionally, tdTomato expression was reduced in OPCs (37.9% ± 2.5%; 424 
one-way ANOVA F(4, 10)= 201.3, P<0.0001 with Tukey’s multiple comparisons test) 425 
and DCs (41.5% ± 2.4%; one-way ANOVA F(4, 10)= 519.5, P<0.0001 with Tukey’s 426 
multiple comparisons test; Figure 9E-G, O-P, Table 1) compared to 3 mg/40 g given at 427 
either P0 (77.7% ± 3.4% OPCs and 77.9 ± 2.4% DCs) or P0/P1 (70.1% ± 2.6% OPCs 428 
and 76.1% ± 0.1% DCs).  429 
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 430 
Discussion  431 
Advances in the science of genetic modification have produced an arsenal of tools that 432 
can be used to study the expression or deletion of specific genes in specific cell types. 433 
This has allowed the development of more targeted therapeutics, as well as broadened 434 
our understanding of living organisms on a cellular and genetic level. To better employ 435 
these tools, we should understand their capabilities and limitations. To that end, we 436 
have endeavored to provide a guide for the use of four CreER mouse lines that are 437 
commonly used in the investigation of the neonatal organ of Corti. We were able to 438 
reduce HC labeling and increase labeling of SC subpopulations by reducing the 439 
tamoxifen dose when Fgfr3-iCreERT2 mice were paired with the tdTomato reporter. In 440 
addition, changing to the CAG-eGFP reporter achieved this goal for both Fgfr3-iCreERT2 441 
and Sox2CreERT2 mice; however this also reduced the total amount of SC labeling. Both 442 
the remaining two CreER lines only labeled SCs with the previously used tamoxifen 443 
doses and no changes in tamoxifen dose altered the expression pattern in Prox1CreERT2 444 
mice. However, a handful of HCs in the apical tip of the cochlea were labeled when we 445 
increased the tamoxifen dose. Altering tamoxifen dose had little impact on Plp-CreERT2 446 
activity. Although when paired with the CAG-eGFP reporter, the number of labeled 447 
PCs/DCs decreased, fewer IPhCs/BCs labeled as well. Importantly, we learned that for 448 
all CreER lines a single dose of tamoxifen at P0 is equivalent to doses given at both P0 449 
and P1 using the tdTomato reporter. This is an important finding because reduced 450 
tamoxifen exposure may reduce toxicity and mortality. 451 
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The four CreER lines we chose to study use promoters expressed at high levels in 453 
postnatal SCs to drive expression of CreER and therefore their expression patterns 454 
were previously expected to label only those cell types. However, low levels of Fgfr3 455 
and Sox2 expression have been detected in some HCs at P1-2 using single-cell RNA-456 
seq analyses (Burns et al., 2015; Waldhaus et al., 2015), which correspond with our 457 
results using Sox2CreERT2 and Fgfr3-iCreERT2. Interestingly, Fgfr3-iCreERT2 HC 458 
expression occurred primarily in OHCs, with only a handful of labeled IHC in the apical 459 
tip. Fgfr3 expression begins at approximately embryonic day (E) 15.5 in the region 460 
where PCs, DCs, and OHCs will form (Peters et al., 1993; Pirvola et al., 1995; Mueller 461 
et al., 2002; Hayashi et al., 2007). Therefore it is possible that Fgfr3 is not expressed in 462 
the progenitor cells that give rise to IHCs.  Alternatively, since Fgfr3-iCreERT2 is a 463 
transgenic allele, expression could be affected by the location of the transgene insertion 464 
site in the genome. Importantly, reducing the tamoxifen dose 10-fold (from 3 mg/40 g 465 
given at both P0/P1 to 0.3 mg/40 g given at P1 only) caused a significant reduction in 466 
the amount of labeled HCs (from ~44% to ~ 4%), while there was a minimal reduction in 467 
PC and DC labeling. In contrast, Sox2CreERT2 activity was detected in both IHCs and 468 
OHCs. This was expected since Sox2 is expressed throughout the developing cochlea 469 
(Kiernan et al., 2005; Hume et al., 2007; Dabdoub et al., 2008). In addition, immature 470 
HCs are known to express Sox2 in the first postnatal week (Kiernan et al., 2005; Hume 471 
et al., 2007; Walters et al., 2015) which overlaps with the ages when tamoxifen was 472 
injected. When the Rosa26tdTomato reporter was paired with Sox2CreERT2, the number of 473 
tdTomato-positive HCs did not change with varying doses of tamoxifen. Switching to the 474 
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CAG-eGFP reporter was able to reduce HC expression (from ~ 35% to ~3%), however 475 
it also reduced SC labeling (~100% to ~66%).  476 
 477 
Two of the four CreER lines investigated (Sox2CreERT2 and Fgfr3-iCreERT2) expressed 478 
an apical to basal decreasing gradient of reporter expression in HCs with both 479 
ROSA26tdTomato and CAG-eGFP reporter lines. Prox1CreERT2 also showed an apical to 480 
basal decreasing gradient of reporter expression in SC subtypes. Cochlear HCs and 481 
SCs are derived from the same pool of progenitor cells (Yang et al., 2010; Cai et al., 482 
2013; Driver et al., 2013) and the organ of Corti is still maturing during the first postnatal 483 
week. Therefore genes necessary for progenitor cells are being downregulated, while 484 
those required for the transition from a progenitor cell fate to a HC or SC fate are being 485 
upregulated during the first few days after birth. Atoh1 is one of the first genes to be 486 
expressed prior to HC commitment and is upregulated at ~E13.5 in the basal turn of the 487 
cochlea (Woods et al., 2004). Between ~E13.5 and E15.5, Atoh1 expression extends 488 
throughout the rest of the cochlea allowing IHCs to differentiate first, followed by OHCs 489 
and then SCs (Kelley, 2007). Therefore, cells in the basal turn of the cochlea are 490 
approximately two days more mature than cells in the apical turn. Genes that are 491 
expressed in early cochlear differentiation like Sox2, Prox1, and Fgfr3 would have 492 
higher expression levels in the less mature cells of the apical turn at P0, matching the 493 
gradient of CreER activity we observed. However, the lack of gradient seen for SCs in 494 
Sox2CreERT2 mice likely occurred because expression of Sox2 persists in SCs throughout 495 
the life of the animal (Oesterle et al., 2008). Interestingly, Plp-CreERT2 showed the 496 
opposite gradient with increased numbers of labeled IPhCs/BCs and DCs in middle and 497 
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basal turns compared to the apex. Maturation of the organ of Corti also occurs in a 498 
wave from the base to the apex of the cochlea and therefore genes required for 499 
differentiation are first expressed in the base. Little is known about how Plp expression 500 
patterns change in the developing cochlea. However our data may suggest that Plp is 501 
expressed later than Sox2, Prox1, and Fgfr3 and only in cells that have committed to a 502 
SC fate as part of the maturation process.  503 
 504 
Of note, Prox1CreERT2 labeled more OPCs and DCs compared to IPCs. This was 505 
somewhat surprising since PROX1 is detected in all IPCs using immunostaining 506 
(Bermingham-McDonogh et al., 2006; Cox et al., 2014), however there are known 507 
differences between IPCs located in the medial compartment of the cochlea and 508 
OPCs/DCs located in the lateral compartment. For example, Hes5 is detected in OPCs, 509 
DCs, and IPhCs/BCs, but not IPCs (Cox et al., 2014) and CD44 is expressed only in 510 
OPCs (Hertzano et al., 2010). Similarly, Lgr5 is expressed in IPCs, IPhCs/BCs, and the 511 
third row of DCs, but not in the rest of the DC pool or in OPCs (Chai et al., 2011; Shi et 512 
al., 2012). Taken together, even though IPCs and OPCs are both classified as PCs and 513 
have similar morphologies, they are very distinct cell types. Another interesting result 514 
obtained with Prox1CreERT2 was the expression of the tdTomato reporter in a handful of 515 
HCs in the apical tip when the highest tamoxifen dose (5 mg/40 g, P0/P1) was given. In 516 
the embryonic cochlea, Prox1 is expressed in progenitor cells beginning at ~E14.5 and 517 
is downregulated in cells as they take on a HC fate. By ~E18.5 Prox1 is not detectable 518 
in HCs using immunostaining (Bermingham-McDonogh et al., 2006); however, the 519 
sensitivity of antibodies is known to be limited and low levels of Prox1 may persist in 520 
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neonatal HCs of the apical turn that is revealed when a high dose of tamoxifen is 521 
combined with the ROSA26tdTomato reporter. 522 
 523 
Interestingly, Sox2CreERT2 showed differential Cre leakiness when paired with the two 524 
different reporter lines. Cre leakiness refers to the phenomenon where some CreER 525 
molecules are able to enter the nucleus and excise loxP sites in the absence of 526 
tamoxifen. With the Rosa26tdTomato reporter, there were several tdTomato-positive SCs 527 
in the organ of Corti, but no eGFP-positive SCs were detected when the CAG-528 
eGFP+/loxP reporter was used. Because Rosa26tdTomato produces a more stable and 529 
brighter fluorescent protein than CAG-eGFP+/loxP (Madisen et al., 2010), it is possible 530 
that smaller quantities of CreER enzyme that translocated into the nucleus in the 531 
absence of tamoxifen were sufficient to induce tdTomato expression. However, no 532 
tdTomato-positive cells were detected in the controls for Fgfr3-iCreERT2, Plp-CreERT2, 533 
or Prox1CreERT2. 534 
 535 
 536 
For this study, we used two reporter lines to assess the activity of four CreER lines in 537 
the neonatal organ of Corti. However, each floxed allele is different because the location 538 
of the loxP sites within the gene and the distance between loxP sites affects the 539 
efficiency of the Cre enzyme to bind and excise DNA located between loxP sites (Sauer 540 
and Henderson, 1989; Kuhn et al., 1995; Feltri et al., 1999; Kellendonk et al., 1999).  541 
While our study is primarily useful for fate-mapping purposes, it is difficult to translate 542 
the reporter expression patterns we measured to other floxed alleles. Some alleles may 543 
be similar to the ROSA26tdTomato reporter, while others may closely resemble the CAG-544 
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eGFP reporter line. This illustrates the importance of using more than one reporter line 545 
to understand the expression pattern of any CreER line used to delete or overexpress a 546 
gene. In addition, it would be wise to use immunostaining to confirm that the gene 547 
deletion/overexpression pattern matches the reporter data.  Overall, the best method for 548 
CreER induction when using the ROSA26tdTomato reporter appears to be one injection of 549 
tamoxifen at 3 mg/40 g given at P0 because it induces similar CreER activity as two 550 
injections without the increased risk of toxicity. Depending on the goal of the study, 551 
either the ROSA26tdTomato reporter or CAG-eGFP reporter is valuable, however the 552 
CAG-eGFP labeled fewer cells with all CreER lines investigated.   553 
 554 
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 769 
Figure 1. Fgfr3-iCreERT2 is expressed in the majority of PCs/DCs. A, Cross-770 
sectional view of the mouse organ of Corti with SC subtypes highlighted in different 771 
colors. The tunnel of Corti is partially open to represent the immature state of the 772 
neonatal cochlea. GER, greater epithelial ridge; SGN, spiral ganglion neurons. B, 773 
Quantification of total reporter-positive SCs in Fgfr3-iCreERT2/+::ROSA26tdTomato/+ mice 774 
or Fgfr3-iCreERT2/+::CAG-eGFP+/loxP mice given different doses of tamoxifen (TAM). 775 
Cells were quantified in two randomly chosen 200 µm regions per cochlear turn, 776 
averaged, and expressed as a percentage of labeled cells compared to total cells. 777 
(**P<0.01, ***P<0.001 as determined by a two-way ANOVA F(3,24)=274.5 with a 778 
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Tukey’s post-hoc test)  (N =3-4). Representative confocal images of tdTomato (red) 779 
expression in Fgfr3-iCreERT2/+::ROSA26tdTomato/+ controls without tamoxifen (C-E) and 780 
those given various doses of tamoxifen (F-H”’). Representative confocal images of 781 
eGFP (green) expression in Fgfr3-iCreERT2/+::CAG-eGFP+/loxP controls without 782 
tamoxifen (I-K) and those given various doses of tamoxifen (L-N”’). Optical cross 783 
sections showing that the location of tdTomato (H’-H”’) and eGFP (N’-N”’) expression 784 
is primarily in SCs. Scale bar in C: 25 μm and in H’ and N’: 6.25 μm.  785 
 786 
Figure 2. Fgfr3-iCreERT2/+::ROSA26tdTomato/+ is robustly expressed in OHCs in an 787 
apical to basal gradient. A, For quantification with the ROSA26tdTomato/+ reporter line, 788 
the entire cochlea was imaged, measured, and divided into six equal sections. A, apex 789 
and B, base. B, Quantification of reporter-positive OHCs in Fgfr3-790 
iCreERT2/+::ROSA26tdTomato/+ mice given different doses of tamoxifen (TAM). All cells 791 
were quantified in each of the six segments, averaged, and expressed as a percentage 792 
of labeled cells compared to total cells. (N =3-4). Representative confocal images of 793 
tdTomato (red) expression in Fgfr3-iCreERT2/+::ROSA26tdTomato/+ controls without 794 
tamoxifen (C-E) and those given various doses of tamoxifen (F-K). L-M, higher 795 
magnification images from regions marked in H and K respectively. Scale bars: 25 μm.  796 
 797 
Figure 3. Fgfr3-iCreERT2/+::CAG-eGFP+/loxP  labels fewer HCs except for the apical 798 
tip of the cochlea. A, For quantification with the CAG-eGFP reporter line, the cochlea 799 
was divided into two sections: the apical most 250 µm and the rest of the cochlea.  A, 800 
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apex and B, base. B, Quantification of reporter-positive OHCs in Fgfr3-iCreERT2/+::CAG-801 
eGFP+/loxP  mice given different doses of tamoxifen (TAM). All cells were quantified in 802 
the two segments, averaged, and expressed as a percentage of labeled cells compared 803 
to total cells. (*P<=0.0101, as determined by a paired Student’s t test t(2)= 9.867)  (N 804 
=3-4). Representative confocal images of eGFP (green) expression in Fgfr3-805 
iCreERT2/+::CAG-eGFP+/loxP  controls without tamoxifen (C-E) and those given various 806 
doses of tamoxifen (F-K). L-M, higher magnification images from regions marked in H 807 
and K respectively. Scale bars: 25 μm. 808 
 809 
Figure 4. Sox2CreERT2 is expressed in all SCs within the organ of Corti. A, 810 
Quantification of total reporter-positive SCs in Sox2CreERT2+/-::ROSA26tdTomato mice or 811 
Sox2CreERT2+/-::CAG-eGFP+/loxP mice given different doses of tamoxifen (TAM). Cells 812 
were quantified in two randomly chosen 200 µm regions per cochlear turn, averaged, 813 
and expressed as a percentage of labeled cells compared to total cells. (***P<0.0001 as 814 
determined by a two-way ANOVA F(4,33)=462.3 with a Tukey’s post-hoc test)  (N =3-4). 815 
Representative confocal images of tdTomato (red) expression in Sox2CreERT2+/-816 
::ROSA26tdTomato controls without tamoxifen (B-D) and those given various doses of 817 
tamoxifen (E-G”’). Representative confocal images of eGFP (green) expression in 818 
Sox2CreERT2+/-::CAG-eGFP+/loxP controls without tamoxifen (H-J) and those given various 819 
doses of tamoxifen (K-M”’). Optical cross sections showing location of tdTomato (G’-820 
G”’) and eGFP (M’-M”’) expression is in SCs and some HCs. Scale bar in B: 25 μm 821 
and in G’ and M’: 6.25 μm.  822 
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 823 
Figure 5. Sox2CreERT2+/-::ROSA26tdTomato is expressed in a large number of HCs in a 824 
descending apical to basal gradient. A, Quantification of reporter-positive HCs in 825 
Sox2CreERT2+/-::ROSA26tdTomato mice given different doses of tamoxifen (TAM). All cells 826 
were quantified in each of the six segments labeled in Figure 2A, averaged, and 827 
expressed as a percentage of labeled cells compared to total cells. (For comparison of 828 
OHCs ***P = 0.00005 as determined by a Pearson correlation coefficient r2 = 0.994, for 829 
comparison of IHCs ***P = 0.0003 as determined by a Pearson correlation coefficient r2 830 
= 0.985) (N =3-4). Representative confocal images of tdTomato (red) expression in 831 
Sox2CreERT2+/-::ROSA26tdTomato controls without tamoxifen (B-D) and those given various 832 
doses of tamoxifen (E-J). K-L, higher magnification images from regions marked in G 833 
and J respectively. Scale bars: 25 μm. 834 
 835 
Figure 6. Sox2CreERT2+/-::CAG-eGFP+/loxP  labels fewer HCs except for the most 836 
apical tip of the cochlea. A, Quantification of reporter-positive HCs in Sox2CreERT2+/-837 
::CAG-eGFP+/loxP  mice given different doses of tamoxifen (TAM). All cells were 838 
quantified in the two segments labeled in Figure 3A, averaged, and expressed as a 839 
percentage of labeled cells compared to total cells. (N =3-4). Representative confocal 840 
images of eGFP (green) expression in Sox2CreERT2+/-::CAG-eGFP+/loxP controls without 841 
tamoxifen (B-D) and those given various doses of tamoxifen (E-J). K-L, higher 842 
magnification images from regions marked in G and J respectively. Scale bars: 25 μm.  843 
 844 
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Figure 7. Targeting of Plp-CreERT2 to IPhCs/BCs increased when the CAG-eGFP 845 
reporter was used.   A, Quantification of total reporter-positive SCs in the three 846 
cochlear turns of Plp-CreERT2/+::ROSA26tdTomato or Plp-CreERT2/+::CAG-eGFP+/loxP mice 847 
given different doses of tamoxifen (TAM). Cells were quantified in two randomly chosen 848 
200 µm regions per cochlear turn, averaged, and expressed as a percentage of labeled 849 
cells compared to total cells. Representative confocal images of tdTomato (red) 850 
expression in Plp-CreERT2/+::ROSA26tdTomato controls without tamoxifen (B-D) and those 851 
given various doses of tamoxifen (E-J). Representative confocal images of eGFP 852 
(green) expression in Plp-CreERT2/+::CAG-eGFP+/loxP controls without tamoxifen (K-M) 853 
and those given various doses of tamoxifen (N-S). Scale bar: 25 μm. (For comparison 854 
among cochlear turns within the same tamoxifen dosing paradigm: 3 mg/40 g tamoxifen 855 
dose at P0 only *P<0.05 as determined by a one-way ANOVA F(1.016, 2.031)=7.435 856 
with a Tukey’s post-hoc test, for the 3 mg/40 g tamoxifen dose at P0/P1 **P<0.01as 857 
determined by a one-way ANOVA F(1.346, 4.038)=129.5 with a Tukey’s post-hoc test. 858 
For comparison across tamoxifen dosing paradigms: *P<0.05 and ***P<0.001 as 859 
determined by a two-way ANOVA F(6,44)=40.9 with a Tukey’s post-hoc test.)  (N =3-4). 860 
 861 
Figure 8. Quantification of reporter expression among SC subtypes in Plp-862 
CreERT2 mice. SC subtypes that expressed the tdTomato or eGFP reporter were 863 
quantified as described in 7A. A, IPhCs/BCs (For comparison among cochlear turns 864 
within the same tamoxifen dosing paradigm: ROSA26tdTomato reporter with tamoxifen at 865 
P0/P1 ***P<0.001 as determined by a one-way ANOVA F(1.313, 3.940)=71.03 with a 866 
Tukey’s post-hoc test; and CAG-eGFP+/loxP reporter with tamoxifen at P0  *P<0.05, 867 
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***P<0.001 as determined by a one-way ANOVA F(1.012, 2.025)=268.8 with a Tukey’s 868 
post-hoc test. For comparison across tamoxifen dosing paradigms: **P<0.01 and 869 
***P<0.001 as determined by a two-way ANOVA F(6,45)=97.06 with a Tukey’s post-hoc 870 
test). B, IPCs (For comparison across tamoxifen dosing paradigms: *P<0.05 as 871 
determined by a two-way ANOVA F(6,45)=6.017 with a Tukey’s post-hoc test). C, OPCs 872 
(For comparison across tamoxifen dosing paradigms: *P<0.05 as determined by a two-873 
way ANOVA F(6, 60)=8.524 with a Tukey’s post-hoc test). D, DCs (For comparison 874 
among cochlear turns within the same tamoxifen dosing paradigm: ROSA26tdTomato 875 
reporter with tamoxifen at P0/P1 *P<0.05 as determined by a one-way ANOVA F(1.193, 876 
3.579)=39.29 with a Tukey’s post-hoc test and ROSA26tdTomato reporter with tamoxifen 877 
at P1 *P<0.05 as determined by a one-way ANOVA F(2, 6)=5.189 with a Tukey’s post-878 
hoc test. For comparison across tamoxifen dosing paradigms: *P<0.05 and **P<0.01 as 879 
determined by a two-way ANOVA F(6,45)=6.313 with a Tukey’s post-hoc test) (N =3-4). 880 
 881 
Figure 9. Targeting of Prox1CreERT2 to PCs and DCs was not altered with changes 882 
in tamoxifen induction paradigm.   A, Quantification of total reporter-positive SCs in 883 
the three cochlear turns of Prox1CreERT2+/-::ROSA26tdTomato or Prox1CreERT2+/-::CAG-884 
eGFP+/loxP mice given different doses of tamoxifen (TAM). Cells were quantified in two 885 
randomly chosen 200 µm regions per cochlear turn, averaged, and expressed as a 886 
percentage of labeled cells compared to total cells. (For comparison among cochlear 887 
turns within the same tamoxifen dosing paradigm: 3 mg/40g tamoxifen dose at P0/P1 888 
*P<0.05 as determined by a one-way ANOVA F(1.018, 2.036)=37.08 with a Tukey’s 889 
post-hoc test; and 5 mg/40g tamoxifen dose *P<0.05 and **P<0.01 as determined by a 890 
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one-way ANOVA F(1,2)=144.1 with a Tukey’s post-hoc test. For comparison across 891 
tamoxifen dosing paradigms: **P<0.01 and ***P<0.001 as determined by a two-way 892 
ANOVA F(4,30)=151.8 with a Tukey’s post-hoc test) (N =3-4). Representative confocal 893 
images of tdTomato (red) expression in Prox1CreERT2+/-::ROSA26tdTomato controls without 894 
tamoxifen (B-D) and those given various doses of tamoxifen (E-M). N-P, SC subtypes 895 
that expressed the tdTomato reporter were quantified as described in A. N, IPCs (For 896 
comparison among cochlear turns within the same tamoxifen dosing paradigm: 3 897 
mg/40g tamoxifen dose at P0/P1 **P<0.01 as determined by a one-way ANOVA 898 
F(1.021, 2.042)=35.11 with a Tukey’s post-hoc test; and 5 mg/40g tamoxifen dose 899 
*P<0.05 as determined by a one-way ANOVA F(1.445, 2.890)=47.77 with a Tukey’s 900 
post-hoc test. For comparison across tamoxifen dosing paradigms: *P<0.05, **P<0.01, 901 
and ***P<0.001 as determined by a two-way ANOVA F(4,30)=24.63 with a Tukey’s 902 
post-hoc test).  O, OPCs (For comparison among cochlear turns within the same 903 
tamoxifen dosing paradigm: 5 mg/40g tamoxifen dose *P<0.05 as determined by a one-904 
way ANOVA F(1.427, 2.854)=37.35 with a Tukey’s post-hoc test. For comparison 905 
across tamoxifen dosing paradigms: **P<0.01 and ***P<0.001 as determined by a two-906 
way ANOVA F(4,30)=139.5 with a Tukey’s post-hoc test).  P, DCs (For comparison 907 
among cochlear turns within the same tamoxifen dosing paradigm: 5 mg/40g tamoxifen 908 
dose *P<0.05, **P<0.01 as determined by a one-way ANOVA F(1.156, 2.911)=94.69 909 
with a Tukey’s post-hoc test. For comparison across tamoxifen dosing paradigms: 910 
***P<0.001 as determined by a two-way ANOVA F(4,30)=231.2 with a Tukey’s post-hoc 911 
test). (N =3-4). O-Q, Representative confocal images of a tdTomato+ HC (arrow) in 912 
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Prox1CreERT2+/-::ROSA26tdTomato mice given the highest dose of tamoxifen (5mg/40g, 913 
P0/P1). Scale bars: 25 μm.  914 
 915 
Table 1: Summary of reporter labeled HC and SC subtypes in Fgfr3-iCreERT2/+, 916 
Sox2CreERT2+/-, Plp-CreERT2, and Prox1CreERT2+/- mice. Quantification of tdTomato-917 
positive or eGFP-positive cells was performed as described in Figures 1B, 2A, and 3A. 918 
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Segment 1 Segment 2 Segment 3 Segment4 Segment5 Segment 6
SCs 77.7% ± 4.9%
OHCs 14.6% ± 10.6% 2.9% ± 2.5% 0.3% ± 0.3% 0.3% ± 0.2% 0.0% ± 0.0% 0.2% ± 0.2% 3.9% ± 2.2%
SCs 94.4% ± 5.5%
OHCs 98.5% ± 0.7% 77.3% ± 3.8% 50.5% ± 5.1% 19.8% ± 3.5% 7.6% ± 0.9% 13.2% ± 3.1% 43.8% ± 2.9%
SCs 99.9% ± 0.0%
HCs 97.2% ± 1.6% 68.3% ± 11.0% 25.1 ± 10.0% 7.6% ± 2.2% 2.6% ± 1.8% 6.0% ± 2.7 34.5% ± 4.7%
SCs 100.0% ± 0.0%
HCs 97.2% ± 1.7% 66.9% ± 10.2% 31.7% ± 11.2% 10.2% ± 3.8% 3.2% ± 1.2% 2.7% ± 1.2% 35.3% ± 4.8%
IPhCs/BCs 72.8% ± 5.4%
IPCs 7.3% ± 0.7%
OPCs 8.9% ± 1.3%
DCs 10.9% ± 2.8%
IPhCs/BCs 71.7% ± 4.3%
IPCs 9.9% ± 2.6%
OPCs 8.1% ± 2.8%
DCs 8.8% ± 2.0%
IPhCs/BCs 72.4% ± 3.1%
IPCs 13.5% ± 4.6%
OPCs 10.6% ± 2.0%
DCs 15% ± 2.9%
IPCs 16.8% ± 4.0%
OPCs 37.9% ± 2.5%
DCs 41.5% ± 2.4%
IPCs 33.4% ± 2.4%
OPCs 77.7% ± 3.4%
DCs 77.9% ± 4.2%
IPCs 25.1% ± 2.9%
OPCs 70.1% ± 2.6%
DCs 76.1% ± 0.1%
IPCs 24.5% ± 0.9% 
OPCs 71.4% ± 1.3%
DCs 79.5% ± 0.4%
Apical Tip Whole cochlea
SCs 37.8% ± 3.4%
OHCs 40.5% ± 6.1% 5.8% ± 2.6%
SCs 66.0% ± 5.9%
HCs 44.8% ± 10.8% 3.2% ± 0.4%
IPhCs/BCs 26.0% ± 4.8%
IPCs 0.3% ± 0.3%
OPCs 0.3% ± 0.3%
DCs 2.6% ± 2.1%
IPhCs/BCs 29.4% ± 3.7%
IPCs 8.4% ± 7.1%
OPCs 8.1% ± 7.4%
DCs 9.0% ± 8.6%
9.1% ± 7.5%
8.4% ± 7.5%
12.0% ± 11.4%
43.8% ± 3.9%
0.0% ± 0.0%
0.0% ± 0.0%
7.3% ± 5.8%
5.8% ± 5.8%
24.3% ± 5.9%
0.9% ± 0.9%
0.0% ± 0.0%
1.1% ± 0.8%
28.2% ± 2.1%
5.9% ± 4.8%
38.1% ± 3.9%
9.8% ± 9.4%
7.4% ± 1.2%
88.5% ± 2.2%
45.9% ± 1.6%
69.0% ± 2.9% 56.8% ± 2.6%
75.4% ± 0.8% 69.3% ± 1.6%
14.5% ± 2.6% 11.1% ± 0.7%
88.4% ± 1.8%
93.6% ± 0.8%
89.6% ±  3.0% 61.7% ± 4.0%
77.7% ± 3.3% 69.0% ± 4.4%
15.7% ± 3.4%
9.8% ± 2.8%
3.9% ± 1.0%
29.3% ± 4.7%
30% ± 11.3% 3.2% ± 1.7%
32.5% ± 13.3%
91.5% ± 2.6%
8.5% ± 2.4%
87.1% ± 2.6%
7.2% ± 4.4%
2.0% ± 1.1%
13.7% ± 5.0%
89.2% ± 3.7%
14.5% ± 1.7%
6.7% ± 3.8% 18.2% ± 5.2%
3.5% ± 2.4%
29.5% ± 4.7%
Mouse Line Dose
Sox2
CreERT2+/-
::CAG-
eGFP
+/loxP
3mg/40g P1
74.0% ± 4.9% 65.7% ± 9.0%
1.6% ± 0.5%
Fgfr3-iCreER
T2/+ 
::CAG-eGFP
+/loxP
3mg/40g P0-
P1
Cell Type
% Labeled Cells
Apex Middle
43.6% ± 6.1% 36.3% ± 1.8% 33.4% ± 3.3%
58.4% ± 5.7%
Base
Rest of Cochlea
5.1% ± 5.1%
15.6% ± 5.5%
12.3% ± 3.7% 
47.9% ± 3.5%
17.2% ± 2.8%
46.3% ± 4.0%
51.6% ±  2.5%
41.9% ± 5.5%
84.3% ± 1.3%
5.8% ± 1.9%
10.1% ± 4.5%
0.0% ± 0.0%
0.8% ± 0.8%
Fgfr3-iCreER
T2/+ 
::ROSA26
tdTomato/+
0.3mg/40g 
P0
3mg/40g P0
Sox2
CreERT2+/-
::ROSA26
tdTomato/+
4.4% ± 2.5%
0.9% ± 0.9%
21.8% ± 10.9%
8.8% ± 7.9%
10.2% ± 8.9%
33.4% ± 6.8% 28.3% ± 5.1%
76.2% ± 5.4% 72.7% ± 5.6%
81.4% ± 3.9% 75.5% ± 1.7%
22.2% ± 6.5%
63.8% ± 4.8%
80.7% ± 0.6%
28.0% ± 8.7%
79.9% ± 2.5%48.2% ± 4.7%
Plp-CreER
T2/+ 
::CAG-
eGFP
+/loxP
3mg/40g P0
3mg/40g P0-
P1
5.5% ± 1.1% 13.6% ± 4.9%
9.3% ± 2.8% 13.9% ± 2.2%
100% ± 0% 
Mouse Line Dose Cell Type Middle Base
99.9% ± 0.1% 99.9% ± 0% 100% ± 0% 
Apex
% Labeled Cells
81.2% ± 5.0% 78.3% ± 3.8%
97.3% ± 2.3% 92.3% ± 4.3%
73.6% ± 5.9%
93.43% ± 6.6%
Whole cochlea
3mg/40g P0-
P1
3mg/40g P0-
P1
100% ± 0% 100% ± 0% 
71.0% ± 13.7%
Prox1
CreERT2+/-
::ROSA26
tdTomato/+
5mg/40g P0-
P1
3mg/40g P0-
P1
3mg/40g P0
0.75mg/40g 
P0
56.8% ± 11.7%
11.0% ± 4.1% 11.4% ± 4.7%
16.4% ± 5.2% 5.9% ± 2.3%
27.4% ± 10.9%
3mg/40g P0
Plp-CreER
T2/+ 
::ROSA26
tdTomato/+
3m/40g     
P0-P1
3mg/40g P1
4.6% ± 1.3% 7.3% ± 3.2%
46.5% ± 4.7% 80.3% ± 4.6%
6.7% ± 2.0% 6.6% ± 3.3%
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